Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update
U Amstutz, LM Henricks, SM Offer… - Clinical …, 2018 - Wiley Online Library
The purpose of this guideline is to provide information for the interpretation of clinical
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …
[PDF][PDF] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 …
U Amstutz, LM Henricks, SM Offer… - Clin …, 2018 - scholarlypublications …
Abstract Fluoropyrimidines (5-fluorouracil, capecitabine) are the mainstay chemotherapeutic
agents for the treatment of many types of cancer. Metabolism of fluoropyrimidines requires …
agents for the treatment of many types of cancer. Metabolism of fluoropyrimidines requires …
[PDF][PDF] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 …
U Amstutz, LM Henricks, SM Offer, J Barbarino… - moodle2.units.it
Background DPYD, the gene encoding dihydropyrimidine dehydrogenase (DPD), the rate-
limiting enzyme for fluoropyrimidine catabolism, spans 950 kb on chromosome 1p22 with …
limiting enzyme for fluoropyrimidine catabolism, spans 950 kb on chromosome 1p22 with …
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update …
U Amstutz, LM Henricks, SM Offer… - Clinical pharmacology …, 2018 - folia.unifr.ch
English The purpose of this guideline is to provide information for the interpretation of
clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be …
clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be …
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
U Amstutz, LM Henricks, SM Offer… - Clinical …, 2018 - mayoclinic.elsevierpure.com
The purpose of this guideline is to provide information for the interpretation of clinical
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
U Amstutz, LM Henricks, SM Offer… - Clinical …, 2018 - pubmed.ncbi.nlm.nih.gov
The purpose of this guideline is to provide information for the interpretation of clinical
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update …
U Amstutz, LM Henricks, SM Offer… - Clinical pharmacology …, 2018 - boris.unibe.ch
The purpose of this guideline is to provide information for the interpretation of clinical
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …
[引用][C] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 …
U Amstutz, LM Henricks, SM Offer, J Barbarino… - Clinical Pharmacology …, 2017 - cir.nii.ac.jp
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine
Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update | CiNii Research CiNii …
Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update | CiNii Research CiNii …
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update …
U Amstutz, LM Henricks, SM Offer… - Clinical …, 2017 - europepmc.org
Abstract Fluoropyrimidines (5-fluorouracil, capecitabine) are the mainstay chemotherapeutic
agents for the treatment of many types of cancer. Metabolism of fluoropyrimidines requires …
agents for the treatment of many types of cancer. Metabolism of fluoropyrimidines requires …
[引用][C] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 …
U Amstutz, LM Henricks, SM Offer… - Clinical …, 2018 - tobias-lib.ub.uni-tuebingen.de
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for
Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing : 2017 Update …
Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing : 2017 Update …